Table 2.
Model parameters by analysis scenario
| Parameter | Scenario 1 | Scenario 2 | Scenario 3 |
|---|---|---|---|
| Initiation of new treatment | 2015 | 2015 | 2015 |
| Patients eligible for treatment (genotypes) | G1 | G1–G4 | G1–G4 |
| Fibrosis status (Metavir score) | ≥F2 | ≥F2 | ≥F2 |
| Rate of eligible patients being treated | 60% | 80% | 90% |
| Rate of patients treated with the new treatment | 10% (2015), 15% (2016), 25% (2018) | 10% (2015), 15% (2016), 25% (2018) | 15% (2015), 25% (2016), 35% (2018) |
| SVR attributed to the new treatment | 90% (naïve) | 90% (naïve) | 90% (naïve) |
| 80% (experienced) | 80% (experienced) | 80% (experienced) | |
| Compliance to new treatment | 80% | 80% | 90% |
| The number of treated patients is | Constant over time (n=11,860) | Increased (from 11,860–12,790) | Increased (from 11,860–16,770) |
Abbreviations: F, fibrosis grade; G, genotype; n, number of subjects; SVR, sustained virological response.